Nutropin AQ

ApprovedSmall molecule

Roche

Nutropin AQ is one of 159 small molecule programs targeting Prader-Willi syndrome. It is currently in Approved.

Indications

Total Trials

Active Trials

158

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prader-Willi SyndromeActive, not recruiting

Cystic FibrosisActive, not recruiting

Growth Hormone DeficiencyActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

GrowthApproved

Prader-Willi SyndromePhase 3

Active, not recruiting

Cystic FibrosisPhase 2/Phase 3

Active, not recruiting

Growth Hormone DeficiencyApproved

Active, not recruiting

Chronic Kidney DiseaseApproved

Active, not recruiting

GrowthApproved

Approved

Competition

Competitive Landscape

540 competitors in Chronic Kidney Disease

#DrugCompanyPhaseTrials

Nutropin AQ

Roche

Approved

1 2

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

16 3

Uloric

Takeda

Preclinical

3 4

Sovaldi

Gilead

Preclinical

1 5

Glucotrol

Pfizer

Preclinical

1 6

Vemlidy

Gilead

Preclinical

1 7

Lorelco

Sanofi

Preclinical

1 8

Activase

Roche

Preclinical

—9

Miochol

BBausch Health Americas, Inc.

Preclinical

2 10

Verquvo

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cystic Fibrosis3 trials

Growth Hormone Therapy for Wasting in Cystic Fibrosis

Terminated·UUniversity of Massachusetts, Worcester·Phase 1·NCT00803179·5 enrolled

Growth Hormone Treatment Study in Children With Cystic Fibrosis

Withdrawn·UUniversity of Texas Southwestern Medical Center·Phase 2/3·NCT00256555

A Study to Evaluate Nutropin AQ for the Treatment of Growth Restriction in Children With Cystic Fibrosis

Completed· Roche logo

Roche·Phase 2·NCT00079742·68 enrolled

Chronic Kidney Disease1 trial

A Study to Optimize Growth Hormone Dosing in Children With Chronic Kidney Disease by Measuring IGF-1 Levels in Blood

Completed·OOregon Health and Science University·Phase 4·NCT00212758·17 enrolled

Growth Hormone Deficiency1 trial

Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia

Completed·—·Phase 4·NCT00140413·20 enrolled

Growth1 trial

Growth Hormone and Chromosome 18q- and Abnormal Growth

Completed·TThe University of Texas Health Science Center at San Antonio·Phase 3·NCT00134420·20 enrolled

Prader-Willi syndrome1 trial

Growth Hormone Use in Adults With Prader-Willi Syndrome

Completed·—·Phase 3·NCT00444964·11 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Nutropin AQ. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nutropin AQ compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nutropin AQ. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Roche

Nutropin AQ

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cystic Fibrosis3 trials

Chronic Kidney Disease1 trial

Growth Hormone Deficiency1 trial

Growth1 trial

Prader-Willi syndrome1 trial

References

Drug Info

Quick Facts

Related News